A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer

BACKGROUND: The mechanisms of resistance to anti-human epidermal growth factor receptor 2 (HER 2) therapies are unclear but may include the tyrosine-protein kinase Met (c-Met), vascular endothelial growth factor (VEGF) and AXL pathways. Foretinib is an inhibitor of c-Met, VEGF receptor 2 (VEGFR-2),...

Descripción completa

Detalles Bibliográficos
Autores principales: Chia, Stephen K., Ellard, Susan L., Mates, Mihaela, Welch, Stephen, Mihalcioiu, Catalin, Miller, Wilson H., Gelmon, Karen, Lohrisch, Caroline, Kumar, Vikaash, Taylor, Sara, Hagerman, Linda, Goodwin, Rachel, Wang, Tao, Sakashita, Shingo, Tsao, Ming S., Eisenhauer, Elizabeth, Bradbury, Penelope
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5414192/
https://www.ncbi.nlm.nih.gov/pubmed/28464908
http://dx.doi.org/10.1186/s13058-017-0836-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5414192/
https://www.ncbi.nlm.nih.gov/pubmed/28464908
http://dx.doi.org/10.1186/s13058-017-0836-3

Ejemplares similares